Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., (based in Tokyo) announced the relocation of its New Jersey-based headquarters to the technologically-advanced and cutting-edge ON3 property in Nutley.

After decades of consolidation by Big Pharma, a host of smaller, younger life sciences companies have found space at legacy research sites throughout the Garden State.

Prism Capital Partners is one of New Jersey’s most active and respected developers focusing on the adaptive re-use and repurposing of excess corporate facilities and turn-of-the-century industrial buildings.